A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

Savas Hatice; Allen Pamela; Evens Andrew M.; Pro Barbara; Dillehay Gary; Rademaker Alfred; Palmer Brett Alan; Advani Ranjana; Gordon Leo I.; Winter Jane N.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

【24h】

A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

机译：II研究（a）封面斑粒子（A）上盖（PEM）（a）上盖（a）上盖（a）通过AVD的前盖，用于前线治疗（a）经典霍奇金淋巴瘤（chl）上盖上限：量化响应以下（a）过帽PEM单药治疗（a）过帽，具有FDG-PLT衍生的代谢肿瘤体积和总损伤糖酵解

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Savas Hatice; Allen Pamela; Evens Andrew M.; Pro Barbara; Dillehay Gary; Rademaker Alfred; Palmer Brett Alan; Advani Ranjana; Gordon Leo I.; Winter Jane N.;
展开▼
作者单位

Northwestern Univ Feinberg Sch Med Dept Radiol Chicago IL 60611 USA;

Emory Univ Winship Canc Inst Decatur GA USA;

Rutgers Canc Inst New Jersey Div Blood Disorders New Brunswick NJ USA;

Northwestern Univ Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Radiol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Robert H Lurie Comprehens Canc Ctr Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Robert H Lurie Comprehens Canc Ctr Chicago IL 60611 USA;

Stanford Univ Stanford CA 94305 USA;

Northwestern Univ Feinberg Sch Med Robert H Lurie Comprehens Canc Ctr Chicago IL 60611 USA;

Robert H Lurie Comprehens Canc Ctr Chicago IL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis [J] . Savas Hatice, Allen Pamela, Evens Andrew M., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：II研究（a）封面斑粒子（A）上盖（PEM）（a）上盖（a）上盖（a）通过AVD的前盖，用于前线治疗（a）经典霍奇金淋巴瘤（chl）上盖上限：量化响应以下（a）过帽PEM单药治疗（a）过帽，具有FDG-PLT衍生的代谢肿瘤体积和总损伤糖酵解
2. Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667 [J] . Mauz-Koerholz C., Kelly K. M., Keller F. G., Klinische Paediatrie . 2020,第2期

机译：2阶段，具有新诊断的古典霍奇金淋巴瘤（CHL）的儿童和年轻成人在儿童和年轻成年人的开放标签研究，早期反应缓慢（SER）至Frontline Chemotherapy：Keynote-667
3. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [J] . Robert Chen, Phillippe Armand, Michelle A Fanale, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087
4. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . Robert Chen, Phillippe Armand, Michelle A Fanale, 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087
5. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087

著录项

相似文献

相关主题

期刊订阅